Mydecine Innovations Group Delays Financial Filings Amid Audit Progress

Mydecine Innovations Group ( (TSE:MYCO) ) has issued an update.

Mydecine Innovations Group Inc. has announced a delay in filing its annual financial statements for the fiscal year ended December 31, 2024, due to reasons previously disclosed. The company is working on completing the audit and expects to provide updates on the timing of its filings by June 26, 2025. During the management cease trade order period, the CEO and CFO are restricted from trading the company’s shares, although public trading continues. Mydecine remains committed to fulfilling regulatory requirements and will issue regular updates until compliance is achieved.

More about Mydecine Innovations Group

Mydecine Innovations Group Inc. is a biotechnology company focused on developing innovative medications and therapies for mental health disorders, such as nicotine addiction and PTSD. The company combines advanced technology with drug discovery and development infrastructure, aiming to create breakthrough treatment solutions. By collaborating with leading specialists, Mydecine seeks to accelerate the development of safer and more effective psychedelic medicines through clinical trials and scientific expertise.

Average Trading Volume: 44,153

Technical Sentiment Signal: Sell

Current Market Cap: C$617.6K

For a thorough assessment of MYCO stock, go to TipRanks’ Stock Analysis page.